Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27746280 | 0.90 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22188704 | 0.88 | HTR1E (0.51) | MEN1LMNAMAPTHTR1EKMT2A | |
| SCHEMBL4176732 | 0.88 | HTR1E (0.51) | MEN1LMNAMAPTHTR1EKMT2A | |
| SCHEMBL13114874 | 0.86 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1SLC6A2SLC6A4 | |
| SCHEMBL4678502 | 0.85 | SLC6A3 (0.60) | CACNA2D1CACNA1BCACNB1SLC6A2SLC6A4 | |
| SCHEMBL5049598 | 0.84 | HTR1E (0.57) | SLC6A2SLC6A3MEN1LMNAMAPT | |
| SCHEMBL4866289 | 0.84 | HTR1E (0.61) | SLC6A2SLC6A3MEN1LMNAMAPT | |
| SCHEMBL29277467 | 0.84 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5051899 | 0.83 | HTR1E (0.59) | SLC6A2SLC6A3MEN1LMNAMAPT | |
| SCHEMBL14453320 | 0.83 | MEN1 (0.59) | SLC6A2SLC6A3MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101048161-A | Arylthiobenzylpiperidine Derivatives | LUNDBECK & CO AS H (DK) | 2007-10-03 | — | — | CN | disclosed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| CN-1268116-A | 3-amidinoaniline derivatives activated blood coagulation factor X inhibitors, and intermediates for producing both | KISSEI PHARMACEUTICAL (JP) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CACNA2D1 4692/4885CACNA1B 3933/4885CACNB1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.